| Literature DB >> 27965999 |
T M Kika1, F B Lepira2, P K Kayembe3, J R Makulo4, E K Sumaili4, E V Kintoki1, J R M'Buyamba-Kabangu1.
Abstract
BACKGROUND: Uncontrolled hypertension remains an important issue in daily clinical practice worldwide. Although the majority of patients are treated in primary care, most of the data on blood pressure control originate from population-based studies or secondary healthcare.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27965999 PMCID: PMC5409201 DOI: 10.5830/CVJA-2016-036
Source DB: PubMed Journal: Cardiovasc J Afr ISSN: 1015-9657 Impact factor: 1.167
Clinical characteristics of the study population as a whole and by blood pressure control status
| Age, years | 64 ± 10 | 64 ± 10 | 64 ± 10 | |
| Gender, % | ||||
| Males | 30 | 27 | 31 | 0.548 |
| Females | 70 | 73 | 69 | |
| DHT, % | 0.179 | |||
| < 1 year | 15 | 16 | 14 | |
| 1–4 years | 29 | 39 | 26 | |
| 5–9 years | 23 | 19 | 24 | |
| ≥ 10 years | 33 | 26 | 35 | |
| FH-HT, % | 50 | 49 | 50 | 0.851 |
| FH-DM, % | 31 | 22 | 34 | 0.166 |
| BMI, kg/m2 | 26 ± 5 | 26 ± 5 | 25 ± 5 | 0.238 |
| WC, cm | 90 ± 11 | 90 ± 11 | 90 ± 11 | 0.953 |
| SBP, mmHg | 151 ± 24 | 122 ± 10 | 160 ± 20 | 0.001 |
| DBP, mmHg | 87 ± 14 | 75 ± 7 | 91 ± 13 | 0.001 |
| MBP, mmHg | 109 ± 16 | 91 ± 7 | 114 ± 13 | 0.001 |
| PP, mmHg | 64 ± 19 | 47 ± 9 | 69 ± 18 | 0.001 |
| Pulse rate, bpm | 76 ± 13 | 77 ± 12 | 77 ± 13 | 0.493 |
| AntiHT regimen, % | ||||
| 1 drug | 66 | 75 | 66 | 0.171 |
| ≥ 2 drugs | 34 | 25 | 34 | |
| Non-drug compliance, % | 42 | 42 | 42 | 0.050 |
Data are expressed as mean ± standard deviation (SD) or relative frequency (%). DHT, duration of hypertension; FH-HT, family history of hypertension; FH-DM, family history of diabetes mellitus; BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean blood pressure; PP, pulse pressure; bpm, beats per minute; AntiHT, antihypertensive.
Antihypertensive and non-antihypertensive drugs in the study population
| Monotherapy, % | 66 | Lipid-lowering drugs, % | 0.3 |
| Diuretic, % | 43 | Uric acid-lowering drugs, % | 0 |
| CCB, % | 11 | Antiplatelet drugs, % | 6 |
| ACEI, % | 11 | NSAIDs, % | 9 |
| CAA, % | 1 | Antidiabetic drugs, | 29 |
| Combined therapy, % | 34 | ||
| Diuretic + ACEI, % | 17 | ||
| Diuretic + CCB, % | 9 | ||
| ACEI + CCB, % | 4 | ||
| Others, % | 4 |
Data are expressed as relative frequency (in percent).
CCB, calcium channel blocker; ACEI, angiotensin converting enzyme inhibitor; CAA, central-acting agents; NSAID, non-steroidal anti-inflammatory drugs.
Fig. 1.Frequency of uncontrolled systolic and diastolic hypertension (Syst-Diast HT) by renal function status (n = 231).
Fig. 2.Frequency of uncontrolled systolic hypertension (Syst HT) by age category (n = 231).
Biological characteristics of the study population as a whole and by blood pressure control status
| Blood glucose, mg/dl | 237 | 115 ± 53 | 104 ± 27 | 119 ± 59 | 0.011 |
| (mmol/l) | 6.38 ± 2.94 | 5.77 ± 1.50 | 6.60 ± 3.27 | ||
| Lipids | 259 | ||||
| TC, mg/dl | 220 ± 58 | 225 ± 60 | 219 ± 57 | 0.548 | |
| (mmol/l) | 5.7 ± 1.5 | 5.83 ± 1.55 | 5.67 ± 1.48 | 0.462 | |
| LDL-C, mg/dl | 135 ± 55 | 139 ± 57 | 134 ± 55 | 0.537 | |
| (mmol/l) | 3.50 ± 1.42 | 3.60 ± 1.48 | 3.47 ± 1.42 | ||
| HDL-C, mg/dl | 63 ± 18 | 62 ± 19 | 63 ± 18 | 0.530 | |
| (mmol/l) | 1.63 ± 0.47 | 1.61 ± 0.49 | 1.63 ± 0.47 | ||
| TG, mg/dl | 111 ± 51 | 118 ± 62 | 109 ± 47 | 0.261 | |
| (mmol/l) | 1.25 ± 0.58 | 1.33 ± 0.70 | 1.23 ± 0.53 | ||
| Creatinine, mg/dl | 255 | 1.04 ± 0.56 | 0.95 ± 0.27 | 1.07 ± 0.62 | 0.133 |
| (μmol/l) | 91.94 ± 9.50 | 83.98 ± 23.87 | 94.59 ± 54.81 | ||
| eGFR, ml/min/0.73 m² | 255 | 82 ± 31 | 86 ± 28 | 81 ± 32 | 0.319 |
| Uric acid, mg/dl | 259 | 6.38 ± 2.50 | 6.60 ± 2.40 | 6.30 ± 2.50 | 0.488 |
Data are expressed as mean ± standard deviation (SD) or relative frequency (%).
TC, total cholesterol ; LDL-C, low-density lipoprotein cholesterol; HDL-C, highdensity lipoprotein cholesterol; TG, triglycerides; eGFR, estimated glomerular filtration rate.
Cardiovascular risk factors among the study population as a whole and by blood pressure control status
| Age, % | 298 | 86 | 87 | 86 | 0.989 |
| Smoking, % | 298 | 3 | 2 | 3 | 0.348 |
| Alcohol, % | 298 | 17 | 18 | 17 | 0.462 |
| Overweight, % | 298 | 35 | 31 | 36 | 0.228 |
| Obesity, % | 298 | 17 | 16 | 22 | 0.228 |
| Central obesity, % | 298 | 66 | 66 | 66 | 1.000 |
| Diabetes, % | 298 | 37 | 22 | 42 | 0.003 |
| Hypercholesterolaemia, % | 259 | 17 | 61 | 51 | 0.229 |
| Low HDL-C, % | 259 | 16 | 13 | 24 | 0.034 |
| Hypertriglyceridaemia, % | 259 | 18 | 18 | 15 | 0.700 |
| Hyperuricaemia, % | 259 | 33 | 33 | 36 | 0.210 |
| Dipstick proteinuria, % | 227 | 16 | 18 | 12 | 0.396 |
| Renal failure, % | 255 | 30 | 12 | 21 | 0.103 |
| ECG-LVH, % | 164 | 21 | 16 | 14 | 0.843 |
| MetS, % | 298 | 10 | 8 | 15 | 0.105 |
| Global CV risk, % | 298 | ||||
| Low | 31 | 69 | 19 | 0.0001 | |
| Moderate | 39 | 18 | 45 | 0.0006 | |
| High/very high | 30 | 13 | 38 | 0.03 |
Data are expressed as mean ± standard deviation (SD) or relative frequency (%).
HDL-C, high-density lipoprotein cholesterol; ECG-LVH, electrocardiographically determined left ventricular hypertrophy; MetS, metabolic syndrome; CV, cardiovascular risk.
Multivariate independent determinants associated with uncontrolled hypertension
| Constant | –1.901 | 0.924 | – | – |
| MetS+ vs MetS– | 0.877 | 0.444 | 2.40 (1.008–5.735) | 0.04 |
Non-compliance vs compliance
B, regression coefficient; SE, standard error; OR, odds ratio; MetS, metabolic syndrome.